Literature DB >> 8758205

BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas.

S Pittaluga1, T A Ayoubi, I Wlodarska, M Stul, J J Cassiman, C Mecucci, H Van Den Berghe, W J Van De Ven, C De Wolf-Peeters.   

Abstract

Chromosomal abnormalities involving 3q27 have recently been associated with diffuse large B-cell lymphomas and, less frequently, with follicular lymphomas. Molecular studies have led to the identification of the BCL-6/LAZ-3 gene, located at 3q27 and coding for a putative zinc-finger protein that might act as a transcriptional regulator during cell differentiation and development. Rearrangement of BCL-6 results in truncation of the gene in its 5' portion, leaving the protein intact; a resultant deregulation of its expression has been hypothesized. In order to test this hypothesis, the expression of BCL-6 protein was investigated in human reactive lymphoid tissue and compared with a group of non-Hodgkin's lymphomas (NHLs) with or without 3q27 anomalies and/or BCL-6 gene rearrangement. BCL-6 protein is consistently expressed in reactive lymphoid tissues, where it is restricted to the follicle centre. The protein is also widely expressed in NHL: all follicular lymphomas tested showed a pattern of expression similar to the reactive B follicle, independently of the presence of BCL-6 gene rearrangement and/or 3q27 anomalies. In the diffuse large B-cell lymphomas, there was more variation in BCL-6 expression, but a correlation with 3q27 anomalies and/or BCL-6 rearrangement was not found. Deregulation of the BCL-6 gene did not result in an aberrant tissue expression as detected by immunohistochemistry.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758205     DOI: 10.1002/(SICI)1096-9896(199606)179:2<145::AID-PATH565>3.0.CO;2-1

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.

Authors:  Akiko Miyagi Maeshima; Hirokazu Taniguchi; Suguru Fukuhara; Noriyuki Morikawa; Wataru Munakata; Dai Maruyama; Sung-Won Kim; Takashi Watanabe; Yukio Kobayashi; Kensei Tobinai; Hitoshi Tsuda
Journal:  Cancer Sci       Date:  2012-08-14       Impact factor: 6.716

Review 2.  Molecular mechanisms of lymphomagenesis through transcriptional disregulation by chromosome translocation.

Authors:  Masao Seto
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients.

Authors:  A K H Shia; G-G Gan; S Jairaman; S-C Peh
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

4.  Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components.

Authors:  Sheren F Younes; Andrew H Beck; Izidore S Lossos; Ronald Levy; Roger A Warnke; Yasodha Natkunam
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

5.  Analysis of follicular lymphoma by dual-color fluorescence in situ hybridization.

Authors:  Dakeun Lee; Jinwon Seo; YoungLyun Oh; Jinman Kim; YoungHyeh Ko
Journal:  Virchows Arch       Date:  2007-11-27       Impact factor: 4.064

Review 6.  Follicular lymphoma: updates for pathologists.

Authors:  Mahsa Khanlari; Jennifer R Chapman
Journal:  J Pathol Transl Med       Date:  2021-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.